MarketPeel
Insider Trading Intelligence
HK

Helen Susan Kim

PRTA
DIRECTOR · PROTHENA CORP PUBLIC LTD CO · CIK 0001422772
FILING MIX · LIFETIME71%/29%
BUYS
10
SELLS
4
TOTAL VALUE
$15.03M
COMPANIES
4
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
186,718
AVG SELL PX
TRADE KIND
SHOWING 14 / 14
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 6 pending
Forward-return performance of every backtestable P/S trade by Helen Susan Kim, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+0.00%-13.70%-2.53%-11.17%-11.17%
14d2+0.00%-0.60%-0.35%-0.25%-0.25%
30d2+0.00%-16.97%-0.46%-16.50%-16.50%
60d2+0.00%-12.69%-4.73%-7.96%-7.96%
90d2+0.00%-20.28%-1.30%-18.97%-18.97%
180d2(2 pending)
1y2(2 pending)
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PRTA · 20,183 shares · as of May 14, 2025
07,50015,00022,50030,000202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 10 buys / 4 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AKTS
AKTIS ONCOLOGY, INC.
PURCHASE
812,455$18.00$14.62M5,671,825Jan 12, 2026Jan 12, 2026View →
AKTS
AKTIS ONCOLOGY, INC.
SALE
14,838,2500Jan 12, 2026Jan 12, 2026View →
AKTS
AKTIS ONCOLOGY, INC.
PURCHASE
4,859,3704,859,370Jan 12, 2026Jan 12, 2026View →
AKTS
AKTIS ONCOLOGY, INC.
SALE
411,7500Jan 12, 2026Jan 12, 2026View →
AKTS
AKTIS ONCOLOGY, INC.
PURCHASE
22,545$18.00$405.8K157,387Jan 12, 2026Jan 12, 2026View →
AKTS
AKTIS ONCOLOGY, INC.
SALE
101,2500Jan 12, 2026Jan 12, 2026View →
AKTS
AKTIS ONCOLOGY, INC.
SALE
3,648,7500Jan 12, 2026Jan 12, 2026View →
AKTS
AKTIS ONCOLOGY, INC.
PURCHASE
134,842134,842Jan 12, 2026Jan 12, 2026View →
PRTA
PROTHENA CORP PUBLIC LTD CO
PURCHASEGRANT
Stock grant
20,18320,183May 14, 2025May 16, 2025View →
PRTA
PROTHENA CORP PUBLIC LTD CO
PURCHASEGRANT
Stock grant
15,00015,000May 15, 2024May 17, 2024View →
PRTA
PROTHENA CORP PUBLIC LTD CO
PURCHASEGRANT
Stock grant
15,00015,000May 17, 2023May 19, 2023View →
PRTA
PROTHENA CORP PUBLIC LTD CO
PURCHASEGRANT
Stock grant
30,00030,000Aug 31, 2022Sep 2, 2022View →
ASMB
ASSEMBLY BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
10,00010,000Jun 11, 2020Jun 15, 2020View →
XCUR
EXICURE, INC.
PURCHASEGRANT
Stock grant
21,69321,693Jun 4, 2020Jun 8, 2020View →
Other insiders · PRTA
Loading peer insiders…
About this filer
CIK 0001422772
ROLE
Director
PRIMARY
PRTA
COMPANIES
4
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001422772DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback